(Q37745070)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20450446%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

review article

1 reference

title

Eribulin mesylate for the treatment of breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20450446%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

1 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20450446%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20450446%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20450446%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20450446%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1587-1593

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20450446%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Large-scale production of pharmaceuticals by marine sponges: sea, cell, or synthesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Peripheral neuropathy induced by microtubule-stabilizing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.486790

10.1517/14656566.2010.486790

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20450446%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference